Pesquisar
Ascentage Pharma Group International
AAPGAdicionar à lista de desejos
17.425USD
-0.750-4.16%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
1.61BValor de mercado
--P/L TTM
Mais detalhes de Ascentage Pharma Group International Empresa
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Informações de Ascentage Pharma Group International
Código da empresaAAPG
Nome da EmpresaAscentage Pharma Group International
Data de listagemOct 28, 2019
CEOYang (Dajun)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
Endereço68 Xinqing Road, Suzhou Industrial Park
CidadeSUZHOU
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal- -
Telefone
Sitehttps://www.ascentage.cn/
Código da empresaAAPG
Data de listagemOct 28, 2019
CEOYang (Dajun)
Executivos da empresa Ascentage Pharma Group International
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Shaomeng Wang, Ph.D.
Dr. Shaomeng Wang, Ph.D.
Non-Executive Director, Co-Founder
Non-Executive Director, Co-Founder
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Ascentage Pharma Group International?
Os cinco principais acionistas de Ascentage Pharma Group International são: Dr. Dajun Yang, M.D., Ph.D.
Quantas instituições possuem ações da Ascentage Pharma Group International (AAPG)?
Em 2026Q1, 25 instituições possuíam ações da Ascentage Pharma Group International, com valor de mercado aproximado de 65.84K, representando 0.07% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -220958.00.